U.S., Dec. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07272343) titled 'The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes' on Nov. 16.
Brief Summary: To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.
Study Start Date: F...